Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Xcel Energy Inc (XEL) Price & Performance

BridgeBio Pharma IncTrade
Xcel Energy IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Xcel Energy Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Xcel Energy Inc trades at $77.66 (market cap $48.02B). The key difference: Xcel Energy Inc is far larger — about 2.9× BridgeBio Pharma Inc's market cap, and Xcel Energy Inc pays a 3.08% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOXEL
Market Cap
$16.61B$48.02B
Sector
HealthUtilities
52-Week High
$90.17$83.91
52-Week Low
$47.29$71.75
Enterprise Value
$18.16B$86.33B
Dividend Yield
3.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Xcel Energy Inc

Xcel Energy (XEL) trades at $78.07, up 1.43% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, driven by infrastructure investment recovery. Revenue for 2025 was $14.67B with a net income margin of 15.28%, while the balance sheet shows rising assets and liabilities, with a debt-to-asset ratio of 41.57% in 2024. Recent news highlights community investment and board additions.

The outlook for XEL is supported by a $60 billion capital plan targeting 11% annual rate base growth, but regulatory pushback and affordability concerns pose risks. Analyst consensus is bullish with a $93.80 price target, implying 20% upside, though technical indicators suggest near-term caution. Earnings growth and utility demand trends remain key catalysts for investor returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Xcel Energy Inc

Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan

Read more on XEL